Ochre Bio is a biotechnology company focused on developing treatments for liver disease. The company aims to end liver disease as a silent killer.

Ochre Bio

Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.

Y Combinator

Expa

Selvedge Venture

Hermes-Epitek

Hoxton Ventures

Khosla Ventures

Apollo Health Ventures

BACKED VC

LifeLink Ventures

EIT Health

AixThera

Alice Zhang

Kristen Fortney

Martin Chavez

Bioverge

FAST — by GETTYLAB

Acequia Capital (AceCap)

Milad Alucozai

🚀 Announcing our new multi-year data licence agreement with GSK to investigate the drivers of liver disease!

This partnership will provide GSK with access to our advanced computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets. The data will be used by both GSK and Ochre Bio to build better AI models – allowing for fewer, but more precise, experiments to aid in target choice.

The deal has a total value of up to $37.5m for both co-exclusive and non-exclusive data licences. 

"Data innovation is as important as algorithmic innovation when investing in ML workflows. Both Ochre Bio and GSK share a commitment to providing liver disease patients with more effective medicines and believe in the power of computational modelling to improve therapeutic discovery. These large-scale, causal human datasets will be foundational for our respective liver pipelines." - Jack O'Meara, Co-Founder and CEO.

Read our full announcement ➡️ https://lnkd.in/eeETgHV6

#TeamOchre #biotech #genomics #LiverDisease BACKED VC Khosla Ventures Norrsken VC BoxOne Ventures Hoxton Ventures Apollo Ventures Y Combinator LifeLink Ventures Taavet+Sten SSI Strategy Entrepreneur First Pledge Ventures Alexandria Real Estate Equities, Inc.

🎙️ New podcast episode alert!

Our CSO and Co-Founder Quin Wills, joined Jon Chee on The Biotech Startups Podcast to talk about genetics, bioinformatics, big data, and much more! 

In the four-part podcast, Quin discusses his transition from medicine to genetics, Ochre Bio’s work pioneering RNA therapies for liver diseases, and the importance of challenging the status quo. 

🎧 Listen to Quin discuss why tackling liver disease is important for global health: 
1️⃣ https://lnkd.in/eGGJDvcZ
2️⃣ https://lnkd.in/eHQczYeX
3️⃣ https://lnkd.in/ejiaXCTs
4️⃣ https://lnkd.in/esaevMT9

#TeamOchre #biotech #genomics #LiverDisease

Celebrating Pride! 🏳️‍🌈

Yesterday, Bob Hughes (he/him) from Switchboard - National LGBTQ+ Support Line visited our Oxford Team.

This year the charity celebrated its 50th anniversary so who better to talk to our team about their insights into the LGBTQIA+ community in the UK, as well as how small, actionable changes can create significant support in the workplace and beyond.

Diversity comes in many forms and Pride month is the perfect time to celebrate our LGBTQIA+ colleagues and discuss how we can be better allies.

#TeamOchre #biotech #genomics #LiverDisease #PrideMonth

Join us at Ochre Bio! Exciting opportunities like the one below now open. 

Check out this job at Ochre Bio: Principal Computational Biologist

“Understanding this complex disease requires better model systems and large-scale data” - Nature Portfolio

Great to see our name in this article highlighting how, by spending more time characterising the disease, innovative biotechs are helping expand treatment options for patients ➡️ https://lnkd.in/extD4cmE 

Metabolic dysfunction-associated steatohepatitis (MASH) affects 1.5-6.45% of the global population. But the search for an effective drug has not been easy – with long, unsuccessful and costly clinical trials frustrating companies, investors and patients. 

The recent approval of Madrigal’s resmetirom is great news for MASH patients, signifying a welcome shift in how we treat this disease. We believe that by deepening our understanding of how fibrotic liver diseases develop, we can advance the portfolio of therapeutic options to treat it. A notion shared by Nature Portfolio.

#TeamOchre #biotech #genomics #LiverDisease

🏃‍♂️ Grab your running shoes! To support The British Liver Trust, our CEO Jack O'Meara will be pounding the pavement at the London Landmarks Half Marathon on April 7th. 

So far, Jack is skipping through training milestones (literally), and is gearing up for a respectable finishing time. 

With 20% of the population at risk of liver disease, The British Liver Trust plays a vital role in research, prevention, early diagnosis, and supporting people living with liver disease. Every donation helps us move closer to a future with improved liver health. 

Donate ➡️ https://lnkd.in/ehheJgGb 

#TeamOchre #LiverDisease #LondonLandmarksHalf2024 #SupportLiverTrust

COM:OCHRE-BIO

Ochre Bio

locale

market

industry

website

linkedin

founding date

investor of

Metrics